The management of Regulus Therapeutics last week provided a few new details on the company's pipeline, promising that it would have two microRNA drug candidates ready for clinical trials before the end of next year.

Speaking during Regulus' first quarterly results conference call since it went public, the executives also indicated that the firm's recent fundraising efforts have yielded enough capital to support its operations for three years, which President and CEO Kleanthis Xanthopoulos said has “significantly de-risked the financial profile of the company.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.